Unresectable Hepatocellular Carcinoma Clinical Trial
Official title:
Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more
than 28%. After diagnosis, the average survival rate of patient is less than 50% in 6 month,
less than 24% in 1 year and 5% in 5 year. The TACE treatment, under the theoretical basis of
blood supply of Liver cancer, is obviously better than the other non-surgical therapy, in
terms of tumor regression, AFP decrease, survival time and the evaluation of the quality of
life. However, its overall effect is not yet satisfactory. As a result, concerning the
research of drug for liver cancer and improving the overall efficacy of the treatment of
liver cancer has a very real and important clinical significance and social value. Licartin
(Iodine-131-Labeled Metuximab) injection is a antibody drug with new target and the only
drug that China own the intellectual property rights. It has specific high affinity with
HAb18G/CD147, the liver cell membrane antigen. Labeled 131I is taken to the liver tissue,
owning high-dose concentration and releasing β particles to liver cancer cells to and kill
cancer cells.
The Second Military Medical University, Eastern Hepatobiliary Surgery Hospital, planed to
use the treatment of Licartin combined with TACE for the patients of unresectable
hepatocellular carcinoma and evaluate the difference of tumor size, AFP change, TTP, the
overall survival rate between different treatment group.
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more
than 28%. The TACE treatment, under the theoretical basis of blood supply of Liver cancer,
is obviously better than the other non-surgical therapy, in terms of tumor regression, AFP
decrease, survival time and the evaluation of the quality of life. Licartin injection is a
antibody drug with new target and the only drug that China own the intellectual property
rights. It has specific high affinity with HAb18G/CD147, the liver cell membrane antigen.
Labeled 131I is taken to the liver tissue, owning high-dose concentration and releasing β
particles to liver cancer cells to and kill cancer cells.
The Second Military Medical University, Eastern Hepatobiliary Surgery Hospital, planed to
use the treatment of Licartin combined with TACE for the patients of unresectable
hepatocellular carcinoma and evaluate the difference of tumor size, AFP change, TTP, the
overall survival rate between different treatment group.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00988741 -
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
|
Phase 2 | |
| Recruiting |
NCT03942328 -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT06315101 -
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
|
||
| Not yet recruiting |
NCT04947956 -
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
|
||
| Completed |
NCT01004978 -
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
| Terminated |
NCT03695250 -
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02006030 -
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03896646 -
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
|
N/A | |
| Recruiting |
NCT05135364 -
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
|
Phase 2 | |
| Recruiting |
NCT06117891 -
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
|
||
| Recruiting |
NCT05957640 -
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04736121 -
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
|
N/A | |
| Recruiting |
NCT05168163 -
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03345225 -
A Clinical Study of Precision TACE (P-TACE) With Surefire
|
N/A | |
| Recruiting |
NCT05667064 -
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
|
||
| Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02989870 -
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
|
Phase 1 |